Merck, Iowa firm sign Ebola vaccine licensing deal

WHITEHOUSE STATION, N.J.- Merck& Co., one of the world's top developers and sellers of vaccines, has entered a partnership with a small drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing. The exclusive deal involves a vaccine candidate called rVSV-EBOV that's under early development by BioProtection Systems,...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.